{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T02:47:06Z","timestamp":1782182826696,"version":"3.54.5"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100018936","name":"Universit\u00e4tsklinikum Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018936","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s40273-023-01320-4","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T13:02:54Z","timestamp":1697720574000},"page":"117-131","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2913-1867","authenticated-orcid":false,"given":"Daniel Tobias","family":"Michaeli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0293-9401","authenticated-orcid":false,"given":"Thomas","family":"Michaeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,19]]},"reference":[{"key":"1320_CR1","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1001\/jama.2022.5542","volume":"327","author":"BN Rome","year":"2022","unstructured":"Rome BN, Egilman AC, Kesselheim AS. Trends in prescription drug launch prices, 2008\u20132021. JAMA. 2022;327:2145\u20137.","journal-title":"JAMA"},{"key":"1320_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.06.020","author":"DT Michaeli","year":"2013","unstructured":"Michaeli DT, Michaeli T. Cancer drug prices in the US efficacy, innovation, clinical trial evidence, and epidemiology. Value Health. 2013. https:\/\/doi.org\/10.1016\/j.jval.2023.06.020. (Epub 28 Jul 2023).","journal-title":"Value Health"},{"key":"1320_CR3","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","volume":"121","author":"C Abboud","year":"2013","unstructured":"Abboud C, Berman E, Cohen A, Cortes J, DeAngelo D, Deininger M, et al. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121:4439\u201342.","journal-title":"Blood"},{"key":"1320_CR4","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.amjmed.2009.04.012","volume":"122","author":"DU Himmelstein","year":"2009","unstructured":"Himmelstein DU, Thorne D, Warren E, Woolhandler S. Medical bankruptcy in the United States, 2007: results of a national study. Am J Med. 2009;122:741\u20136.","journal-title":"Am J Med"},{"key":"1320_CR5","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1377\/hlthaff.2012.1263","volume":"32","author":"S Ramsey","year":"2013","unstructured":"Ramsey S, Blough D, Kirchhoff A, Kreizenbeck K, Fedorenko C, Snell K, et al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood). 2013;32:1143\u201352.","journal-title":"Health Aff (Millwood)."},{"key":"1320_CR6","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.1002\/cncr.28262","volume":"119","author":"EE Kent","year":"2013","unstructured":"Kent EE, Forsythe LP, Yabroff KR, Weaver KE, de Moor JS, Rodriguez JL, et al. Are survivors who report cancer-related financial problems more likely to forgo or delay medical care? Cancer. 2013;119:3710\u20137.","journal-title":"Cancer"},{"key":"1320_CR7","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1200\/JCO.2015.64.6620","volume":"34","author":"SD Ramsey","year":"2016","unstructured":"Ramsey SD, Bansal A, Fedorenko CR, Blough DK, Overstreet KA, Shankaran V, et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol. 2016;34:980\u20136.","journal-title":"J Clin Oncol"},{"key":"1320_CR8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.2026","volume":"7","author":"KN Vokinger","year":"2021","unstructured":"Vokinger KN, Hwang TJ, Daniore P, Lee CC, Tibau A, Grischott T, et al. Analysis of launch and postapproval cancer drug pricing, clinical benefit, and policy implications in the US and Europe. JAMA Oncol. 2021;7: e212026.","journal-title":"JAMA Oncol"},{"key":"1320_CR9","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1001\/jama.2020.1012","volume":"323","author":"I Hernandez","year":"2020","unstructured":"Hernandez I, San-Juan-Rodriguez A, Good CB, Gellad WF. Changes in list prices, net prices, and discounts for branded drugs in the US, 2007\u20132018. JAMA. 2020;323:854\u201362.","journal-title":"JAMA"},{"key":"1320_CR10","doi-asserted-by":"publisher","first-page":"e218816","DOI":"10.1001\/jamanetworkopen.2021.8816","volume":"4","author":"BN Rome","year":"2021","unstructured":"Rome BN, Feldman WB, Desai RJ, Kesselheim AS. Correlation between changes in brand-name drug prices and patient out-of-pocket costs. JAMA Netw Open. 2021;4:e218816\u2013e218816.","journal-title":"JAMA Netw Open"},{"key":"1320_CR11","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1001\/jamaoncol.2015.0373","volume":"1","author":"S Mailankody","year":"2015","unstructured":"Mailankody S, Prasad V. Five years of cancer drug approvals: innovation, efficacy, and costs. JAMA Oncol. 2015;1:539\u201340.","journal-title":"JAMA Oncol"},{"key":"1320_CR12","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/S1470-2045(20)30139-X","volume":"21","author":"KN Vokinger","year":"2020","unstructured":"Vokinger KN, Hwang TJ, Grischott T, Reichert S, Tibau A, Rosemann T, et al. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis. Lancet Oncol. 2020;21:664\u201370.","journal-title":"Lancet Oncol"},{"key":"1320_CR13","doi-asserted-by":"publisher","first-page":"pky016","DOI":"10.1093\/jncics\/pky016","volume":"2","author":"TJ Hwang","year":"2018","unstructured":"Hwang TJ, Kesselheim AS, Gyawali B. Affordability and price increases of new cancer drugs in clinical guidelines, 2007\u20132016. JNCI Cancer Spectr. 2018;2:pky016.","journal-title":"JNCI Cancer Spectr"},{"key":"1320_CR14","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S1470-2045(17)30415-1","volume":"18","author":"JC Del Paggio","year":"2017","unstructured":"Del Paggio JC, Sullivan R, Schrag D, Hopman WM, Azariah B, Pramesh CS, et al. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. Lancet Oncol. 2017;18:887\u201394.","journal-title":"Lancet Oncol"},{"key":"1320_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1257\/jep.29.1.139","volume":"29","author":"DH Howard","year":"2015","unstructured":"Howard DH, Bach PB, Berndt ER, Conti RM. Pricing in the market for anticancer drugs. J Econ Perspect. 2015;29:139\u201362.","journal-title":"J Econ Perspect"},{"key":"1320_CR16","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.6004\/jnccn.2020.7574","volume":"18","author":"AP Mitchell","year":"2020","unstructured":"Mitchell AP, Tabatabai SM, Dey P, Ohn JA, Curry MA, Bach PB. The association between clinical value and financial cost of cancer treatments: a cross-sectional analysis. J Natl Compr Cancer Netw. 2020;18:1349\u201353.","journal-title":"J Natl Compr Cancer Netw."},{"issue":"258","key":"1320_CR17","volume":"2020","author":"S Salas-Vega","year":"1982","unstructured":"Salas-Vega S, Shearer E, Mossialos E. Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US. Soc Sci Med. 1982;2020(258): 113042.","journal-title":"Soc Sci Med"},{"key":"1320_CR18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1177\/1758834016644465","volume":"8","author":"D Mengato","year":"2016","unstructured":"Mengato D, Messori A. Pricing of innovative drugs: correlation between incremental cost and survival gain in four countries. Ther Adv Med Oncol. 2016;8:309\u201311.","journal-title":"Ther Adv Med Oncol."},{"key":"1320_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12962-020-00223-x","volume":"18","author":"M Berdud","year":"2020","unstructured":"Berdud M, Drummond M, Towse A. Establishing a reasonable price for an orphan drug. Cost Eff Resour Alloc. 2020;18:31.","journal-title":"Cost Eff Resour Alloc."},{"key":"1320_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-007199","volume":"5","author":"IJ Onakpoya","year":"2015","unstructured":"Onakpoya IJ, Spencer EA, Thompson MJ, Heneghan CJ. Effectiveness, safety and costs of orphan drugs: an evidence-based review. BMJ Open. 2015;5: e007199.","journal-title":"BMJ Open"},{"key":"1320_CR21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1750-1172-6-42","volume":"6","author":"S Simoens","year":"2011","unstructured":"Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011;6:42.","journal-title":"Orphanet J Rare Dis"},{"key":"1320_CR22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.18623","volume":"5","author":"OJ Wouters","year":"2022","unstructured":"Wouters OJ, Berenbrok LA, He M, Li Y, Hernandez I. Association of research and development investments with treatment costs for new drugs approved from 2009 to 2018. JAMA Netw Open. 2022;5: e2218623.","journal-title":"JAMA Netw Open"},{"key":"1320_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-073242","volume":"281","author":"T Michaeli","year":"2023","unstructured":"Michaeli T, J\u00fcrges H, Michaeli DT. FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis. BMJ. 2023;281: e073242.","journal-title":"BMJ"},{"key":"1320_CR24","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S1470-2045(22)00073-0","volume":"23","author":"KN Vokinger","year":"2022","unstructured":"Vokinger KN, Hwang TJ, Carl DL, Laube Y, Ludwig W-D, Naci H, et al. Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis. Lancet Oncol. 2022;23:514\u201320.","journal-title":"Lancet Oncol"},{"key":"1320_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002872","volume":"16","author":"A Sarpatwari","year":"2019","unstructured":"Sarpatwari A, DiBello J, Zakarian M, Najafzadeh M, Kesselheim AS. Competition and price among brand-name drugs in the same class: a systematic review of the evidence. PLOS Med. 2019;16: e1002872.","journal-title":"PLOS Med"},{"key":"1320_CR26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1377\/hlthaff.2018.05147","volume":"38","author":"I Hernandez","year":"2019","unstructured":"Hernandez I, Good CB, Cutler DM, Gellad WF, Parekh N, Shrank WH. The contribution of new product entry versus existing product inflation in the rising costs of drugs. Health Aff (Millwood). 2019;38:76\u201383.","journal-title":"Health Aff (Millwood)."},{"key":"1320_CR27","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1001\/jamaoncol.2016.0648","volume":"2","author":"SB Dusetzina","year":"2016","unstructured":"Dusetzina SB. Drug pricing trends for orally administered anticancer medications reimbursed by commercial health plans, 2000\u20132014. JAMA Oncol. 2016;2:960\u20131.","journal-title":"JAMA Oncol"},{"key":"1320_CR28","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1200\/JCO.2016.72.2124","volume":"36","author":"N Gordon","year":"2018","unstructured":"Gordon N, Stemmer SM, Greenberg D, Goldstein DA. Trajectories of injectable cancer drug costs after launch in the United States. J Clin Oncol. 2018;36:319\u201325.","journal-title":"J Clin Oncol"},{"key":"1320_CR29","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.44923","volume":"5","author":"A Desai","year":"2022","unstructured":"Desai A, Scheckel C, Jensen CJ, Orme J, Williams C, Shah N, et al. Trends in prices of drugs used to treat metastatic non-small cell lung cancer in the US from 2015 to 2020. JAMA Netw Open. 2022;5: e2144923.","journal-title":"JAMA Netw Open"},{"key":"1320_CR30","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.35064","volume":"4","author":"P Liu","year":"2021","unstructured":"Liu P, Dhruva SS, Shah ND, Ross JS. Trends in within-class changes in US average wholesale prices for brand-name medications for common conditions from 2015 to 2020. JAMA Netw Open. 2021;4: e2035064.","journal-title":"JAMA Netw Open"},{"key":"1320_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.4791","volume":"2","author":"NE Wineinger","year":"2019","unstructured":"Wineinger NE, Zhang Y, Topol EJ. Trends in prices of popular brand-name prescription drugs in the United States. JAMA Netw Open. 2019;2: e194791.","journal-title":"JAMA Netw Open"},{"key":"1320_CR32","doi-asserted-by":"publisher","unstructured":"Michaeli DT, Michaeli T, Albers S, Boch T, Michaeli JC.\u00a0Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy. Eur J Health Econ. 2023. https:\/\/doi.org\/10.1007\/s10198-023-01639-x.","DOI":"10.1007\/s10198-023-01639-x"},{"key":"1320_CR33","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s40258-022-00737-w","volume":"20","author":"DT Michaeli","year":"2022","unstructured":"Michaeli DT, Mills M, Kanavos P. Value and price of multi-indication cancer drugs in the USA, Germany, France, England, Canada, Australia, and Scotland. Appl Health Econ Health Policy. 2022;20:757\u201368.","journal-title":"Appl Health Econ Health Policy"},{"key":"1320_CR34","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1377\/hlthaff.2019.01122","volume":"39","author":"VD Lauenroth","year":"2020","unstructured":"Lauenroth VD, Kesselheim AS, Sarpatwari A, Stern AD. Lessons from the impact of price regulation on the pricing of anticancer drugs in Germany. Health Aff (Millwood). 2020;39:1185\u201393.","journal-title":"Health Aff (Millwood)."},{"key":"1320_CR35","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.healthpol.2019.12.006","volume":"124","author":"KN Vokinger","year":"2020","unstructured":"Vokinger KN, Muehlematter UJ. Accessibility of cancer drugs in Switzerland: time from approval to pricing decision between 2009 and 2018. Health Policy. 2020;124:261\u20137.","journal-title":"Health Policy"},{"key":"1320_CR36","unstructured":"Institute for Health Metrics and Evaluation (IHME). GBD Results. Seattle, WA: IHME, University of Washington; 2020. Available at: https:\/\/vizhub.healthdata.org\/gbd-results\/"},{"key":"1320_CR37","doi-asserted-by":"crossref","unstructured":"Michaeli DT, Mills M, Michaeli T, Miracolo A, Kanavos P. Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA. Invest New Drugs. 2022;798\u2013809.","DOI":"10.1007\/s10637-022-01227-5"},{"key":"1320_CR38","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1200\/JCO.22.00535","volume":"40","author":"DT Michaeli","year":"2022","unstructured":"Michaeli DT, Michaeli T. Overall survival, progression-free survival, and tumor response benefit supporting initial FDA approval and indication extension of new cancer drugs, 2003\u20132021. J Clin Oncol. 2022;40:4095\u2013106.","journal-title":"J Clin Oncol"},{"key":"1320_CR39","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMhpr0807774","volume":"360","author":"PB Bach","year":"2009","unstructured":"Bach PB. Limits on Medicare\u2019s ability to control rising spending on cancer drugs. N Engl J Med. 2009;360:626\u201333.","journal-title":"N Engl J Med"},{"key":"1320_CR40","doi-asserted-by":"publisher","first-page":"e1247","DOI":"10.1200\/OP.21.00847","volume":"18","author":"AP Desai","year":"2022","unstructured":"Desai AP, Scheckel CJ, Soderberg LC, Jensen CJ, Orme JJ, Tella SH, et al. Economic cost and sustainability of oral therapies in precision oncology. JCO Oncol Pract. 2022;18:e1247\u201354.","journal-title":"JCO Oncol Pract."},{"key":"1320_CR41","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1086\/467101","volume":"28","author":"GJ Stigler","year":"1985","unstructured":"Stigler GJ, Sherwin RA. The extent of the market. J Law Econ. 1985;28:555\u201385.","journal-title":"J Law Econ"},{"key":"1320_CR42","unstructured":"Bishop S, Baldauf M. Theoretische Grundlagen und praktische Anwendung wettbewerbs\u00f6konomischer Methoden in Bezug auf die Abgrenzung des relevanten Marktes und Fragen zur praktischen Anwendbarkeit des Herfindahl-Hirschman Indexes zur Ermittlung des Konzentrationsgrades. RBB Economics; 2006 [cited 2 Sep 2023]. Available at: https:\/\/www.bwb.gv.at\/fileadmin\/user_upload\/Downloads\/publikationen\/MarktabgrenzungrbbStudiefinal.pdf"},{"key":"1320_CR43","doi-asserted-by":"publisher","first-page":"424","DOI":"10.2307\/1912791","volume":"37","author":"CWJ Granger","year":"1969","unstructured":"Granger CWJ. Investigating causal relations by econometric models and cross-spectral methods. Econometrica. 1969;37:424\u201338.","journal-title":"Econometrica"},{"key":"1320_CR44","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453\u20137.","journal-title":"Lancet"},{"key":"1320_CR45","doi-asserted-by":"publisher","unstructured":"Michaeli DT, Michaeli T, Albers S, Michaeli JC. Clinical benefit, development, innovativeness, trials, epidemiology, and price for cancer drugs and indications with multiple special FDA designations. J Natl Cancer Inst. 2023. https:\/\/doi.org\/10.1093\/jnci\/djad212.","DOI":"10.1093\/jnci\/djad212"},{"key":"1320_CR46","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1007\/s11606-020-05805-2","volume":"35","author":"JD Chambers","year":"2020","unstructured":"Chambers JD, Silver MC, Berklein FC, Cohen JT, Neumann PJ. Orphan drugs offer larger health gains but less favorable cost-effectiveness than non-orphan drugs. J Gen Intern Med. 2020;35:2629\u201336.","journal-title":"J Gen Intern Med"},{"key":"1320_CR47","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s40273-022-01195-x","volume":"40","author":"LZ Rand","year":"2022","unstructured":"Rand LZ, Kesselheim AS. Getting the price right: lessons for medicare price negotiation from peer countries. Pharmacoeconomics. 2022;40:1131\u201342.","journal-title":"Pharmacoeconomics"},{"key":"1320_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140002","volume":"10","author":"T Gammie","year":"2015","unstructured":"Gammie T, Lu CY, Babar ZU-D. Access to orphan drugs: a comprehensive review of legislations, regulations and policies in 35 countries. PLoS ONE. 2015;10: e0140002.","journal-title":"PLoS ONE"},{"issue":"2","key":"1320_CR49","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s43441-021-00364-y","volume":"56","author":"DT Michaeli","year":"2022","unstructured":"Michaeli DT, Yagmur HB, Achmadeev T, Michaeli T. Valuation and returns of drug development companies: lessons for bioentrepreneurs and investors. Ther Innov Regul Sci. 2022;56(2):313\u201322.","journal-title":"Ther Innov Regul Sci."},{"issue":"8","key":"1320_CR50","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s10198-021-01427-5","volume":"23","author":"DT Michaeli","year":"2022","unstructured":"Michaeli DT, Yagmur HB, Achmadeev T, Michaeli T. Value drivers of development stage biopharma companies. Eur J Health Econ. 2022;23(8):1287\u201396.","journal-title":"Eur J Health Econ"},{"key":"1320_CR51","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1377\/hlthaff.2015.1145","volume":"35","author":"CS Bennette","year":"2016","unstructured":"Bennette CS, Richards C, Sullivan SD, Ramsey SD. Steady increase in prices for oral anticancer drugs after market launch suggests a lack of competitive pressure. Health Aff (Millwood). 2016;35:805\u201312.","journal-title":"Health Aff (Millwood)."},{"key":"1320_CR52","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1212\/WNL.0000000000001282","volume":"84","author":"AJ Espay","year":"2015","unstructured":"Espay AJ, Norris MM, Eliassen JC, Dwivedi A, Smith MS, Banks C, et al. Placebo effect of medication cost in Parkinson disease: a randomized double-blind study. Neurology. 2015;84:794\u2013802.","journal-title":"Neurology"},{"key":"1320_CR53","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1001\/jama.299.9.1016","volume":"299","author":"RL Waber","year":"2008","unstructured":"Waber RL, Shiv B, Carmon Z, Ariely D. Commercial features of placebo and therapeutic efficacy. JAMA. 2008;299:1016\u20137.","journal-title":"JAMA"},{"key":"1320_CR54","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/BF02284670","volume":"4","author":"PA Cartwright","year":"1989","unstructured":"Cartwright PA, Kamerschen DR, Huang M-Y. Price correlation and granger causality tests for market definition. Rev Ind Organ. 1989;4:79\u201398.","journal-title":"Rev Ind Organ"},{"key":"1320_CR55","unstructured":"John A. Yarmuth. Inflation Reduction Act of 2022. 2022 [cited 18 Feb 2023]. Available at: https:\/\/www.congress.gov\/bill\/117th-congress\/house-bill\/5376\/text"},{"key":"1320_CR56","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1377\/hlthaff.2020.01442","volume":"40","author":"K-P Chua","year":"2021","unstructured":"Chua K-P, Kimmel LE, Conti RM. Spending for orphan indications among top-selling orphan drugs approved to treat common diseases. Health Aff (Millwood). 2021;40:453\u201360.","journal-title":"Health Aff (Millwood)."},{"key":"1320_CR57","first-page":"16","volume":"2","author":"C Schuler","year":"2019","unstructured":"Schuler C, Opgen-Rhein R, Greer A, Aro G. The International Price Referencing (IPR) conundrum: strategic approaches for practical implementation. Simon-Kucher Partn Healthc Insights. 2019;2:16\u201323.","journal-title":"Simon-Kucher Partn Healthc Insights"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-023-01320-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-023-01320-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-023-01320-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T16:25:53Z","timestamp":1705422353000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-023-01320-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,19]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["1320"],"URL":"https:\/\/doi.org\/10.1007\/s40273-023-01320-4","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,19]]},"assertion":[{"value":"25 September 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DTM and TM had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analyses. Both authors contributed to the study concept and design; acquisition, analysis, or interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; and study supervision. Statistical analysis was performed by DTM.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Open Access funding enabled and organized by Projekt DEAL.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding\/Support"}},{"value":"Daniel Tobias Michaeli and Thomas Michaeli declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All data used in this study were in the public domain. All data relevant to the study are included in the article or are uploaded as supplementary information.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Sharing Statement"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient Consent for Publication"}},{"value":"None needed.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not commissioned; externally peer reviewed.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Provenance and Peer review"}},{"value":"No patients were involved in the conduct of this study.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient and Public Involvement"}}]}}